<div style="margin: 12px 0px; font-family: arial; color: #333333; background: #ffffff; border: solid 4px #e5e5e5; width: 100%; clear: left;"><div class="CM_CTB_Content_Wrap" style="margin: 0px; padding: 0px;background-color: #ffffff;"><div style="border-bottom: solid 1px #dcdcdc; white-space: nowrap; margin-bottom: 8px; background-color: #eeeeee ;background-image: url(http://clipmarks.com/images/source-bg.gif); background-repeat: repeat-x; height: 24px; line-height: 24px; vertical-align: middle; padding-bottom: 4px; color: #666666; font-size: 10px;" ><a href="http://clipmarks.com/clip-to-blog/" title="see clips that are hot right now"><img src="http://content.clipmarks.com/blog_embed/0e23819d-85d6-4ca1-a905-5aea883424cf/9D5D72A8-5F45-49BD-9745-4834004DCFB9/" alt="" width="19" height="19" border="0" style="vertical-align: middle; margin: 0px 4px; display: inline; border: none; float:none;" /></a>clipped from <a title="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100" href="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100" style="font-size: 11px;">www.reuters.com</a></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100"><P>LONDON (Reuters) - The European Medicines Agency has recommended conditional approval of GlaxoSmithKline Plc's new breast cancer pill Tykerb, Europe's biggest drugmaker said on Friday.<SPAN id="midArticle_byline"></SPAN></P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100"><P>The medicine, which is already on sale in the United States, will be marketed as Tyverb in Europe. It is designed to be given in combination with Roche Holding AG's Xeloda for treating patients with advanced or metastatic breast cancer whose tumors overexpress the HER2 protein.</P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100"><P>The news is a boost for Glaxo, which is aiming to increase its position in the fast-growing cancer market.</P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100"><P>The conditional approval -- if endorsed by the European Commission within a couple of months, as expected -- means the drug can sold immediately but that additional clinical data are still required.</P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.reuters.com/article/healthNews/idUSL1464852720071214?feedType=nl&feedName=ushealth1100"><P>Because Tykerb, known generically as lapatinib, is given as a pill it is more convenient than Roche and Genentech Inc's blockbuster Herceptin, which works in a similar way but must be injected.</P></blockquote></div><div style="margin: 0px 6px 6px 4px;"><table style="font-size: 11px;border-spacing: 0px;padding: 0px;" cellpadding="0" cellspacing="0" width="100%"><tr><td style="background:transparent;border-width:0px;padding:0px;">&nbsp;</td><td align="right" style="background:transparent;border-width:0px;padding:0px;width:107px" width="107"><a href="http://clipmarks.com/share/9D5D72A8-5F45-49BD-9745-4834004DCFB9/blog/" title="blog or email this clip"><img src="http://content9.clipmarks.com/images/c2b-foot.png" border="0" alt="blog it" width="107" height="17" style="border-width:0px;padding:0px;margin:0px;" /></a></td></tr></table></div></div>

New from the makers of Clipmarks:  Amplify.com - Don't just share the news...Amplify it!